SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Unlocking the Benefits of Cardiovascular Health Checks in EU Prevention Strategies
Cardiovascular health checks deliver strong clinical, economic and societal value when delivered as structured, risk-based programmes connected to ongoing care. This approach supports EU cardiovascular prevention strategies by catching cardiometabolic risks early and reducing long-term events. Th...
Rui Santos Ivo Advocates for Regulatory Frameworks Innovation at RAPS Euro Convergence 2026
Rui Santos Ivo, President of the INFARMED Board of Directors and Chair of the European Medicines Agency (EMA) Management Board, emphasized the need for regulatory frameworks innovation during the opening session of the Regulatory Affairs Professionals Society (RAPS) Euro Convergence 2026 conferen...
Sandoz Mobile Health Initiative: Empowering Communities Through Accessible Care
Sandoz has launched the Sandoz mobile health initiative in Portugal through its “Sandoz em Marcha” project, sending a mobile health unit to 16 localities over two months to deliver free screenings and health educ...